Hisamitsu Pharmaceutical Co., Inc.

4530

JP3784600003

Pharmaceuticals

Delayed Japan Exchange Other stock markets 02:00:00 2024-07-12 am EDT			5-day change	1st Jan Change
3,954 ^JPY	+0.59%		+5.55%	-8.28%

Jul. 11	Hisamitsu Pharmaceutical's Attributable Profit Jumps Over 18% in Fiscal Q1	MT
Jul. 11	Hisamitsu Pharmaceutical Co., Inc. Provides Commemorative Dividend for the Fiscal Year Ending February 28, 2025	CI

Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 28, 2025

July 11, 2024 at 02:00 am EDT

Hisamitsu Pharmaceutical Co., Inc. provided consolidated earnings guidance for the fiscal year ending February 28, 2025. For the period, the company expected net sales of JPY 152,000 million, operating profit of JPY 14,500 million, profit attributable to owners of parent of JPY 15,800 million and profit per share of JPY 210.83.

Latest news about Hisamitsu Pharmaceutical Co., Inc.

Hisamitsu Pharmaceutical's Attributable Profit Jumps Over 18% in Fiscal Q1	Jul. 11	MT
Hisamitsu Pharmaceutical Co., Inc. Provides Commemorative Dividend for the Fiscal Year Ending February 28, 2025	Jul. 11	CI
Hisamitsu Pharmaceutical Co., Inc. Provides Dividend Guidance for the Second Quarter of Fiscal 2025 and Full Year Ending February 28, 2025	Jul. 11	CI
Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 28, 2025	Jul. 11	CI
Hisamitsu Pharmaceutical Co., Inc.(TSE:4530) dropped from S&P Japan Mid Cap 100	Jun. 23	CI
Tranche Update on Hisamitsu Pharmaceutical Co., Inc.'s Equity Buyback Plan announced on May 23, 2024.	May. 23	CI
Hisamitsu Pharmaceutical Co., Inc.'s Equity Buyback announced on May 23, 2024, has closed with 2,400,000 shares, representing 3.17% for ¥8,901.6 million.	May. 23	CI
Hisamitsu Pharmaceutical Co., Inc. announces an Equity Buyback for 2,400,000 shares, representing 3.17% for ¥8,901.6 million.	May. 23	CI
Hisamitsu Pharmaceutical Co., Inc. authorizes a Buyback Plan.	May. 22	CI
Hisamitsu Pharmaceutical Attributable Profit Up 19% in Fiscal 2024	Apr. 11	MT
Hisamitsu Pharmaceutical Lifts Fiscal-Year Targets as Nine-Month Profit, Net Sales Rise	Jan. 12	MT
Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 29, 2024	Jan. 11	CI
Hisamitsu Pharmaceutical Co., Inc. Announces Dividend for the Second Quarter and Provides Dividend Guidance for the Full Year Ending February 29, 2024	Jan. 11	CI
Tranche Update on Hisamitsu Pharmaceutical Co., Inc.'s Equity Buyback Plan announced on July 13, 2023.	Dec. 26	CI
Hisamitsu Pharmaceutical Co., Inc.'s Equity Buyback announced on July 13, 2023, has closed with 2,000,000 shares, representing 2.58% for ¥9,792.58 million.	Dec. 24	CI
Tranche Update on Hisamitsu Pharmaceutical Co., Inc.'s Equity Buyback Plan announced on July 13, 2023.	Dec. 05	CI
Hisamitsu Pharmaceutical’s Attributable Profit up 29.4% in Fiscal Q2 on Improved Net Sales	23-10-08	MT
Hisamitsu Pharmaceutical Co., Inc. Reports Earnings Results for the Half Year Ended August 31, 2023	23-10-06	CI
Tranche Update on Hisamitsu Pharmaceutical Co., Inc.'s Equity Buyback Plan announced on July 13, 2023.	23-09-04	CI
Hisamitsu Pharmaceutical Attributable Profit More Than Doubles in Fiscal Q1; Shares Climb 11%	23-07-13	MT
Hisamitsu Pharmaceutical Co., Inc. announces an Equity Buyback for 2,000,000 shares, for ¥10,000 million.	23-07-13	CI
Hisamitsu Pharmaceutical Co., Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending February 29, 2024	23-07-13	CI
Hisamitsu Pharmaceutical Co., Inc. Provides Dividend Guidance for the Second Quarter of Fiscal 2024 and Full Year Ending February 29, 2024	23-07-13	CI
Hisamitsu Pharmaceutical Co., Inc. authorizes a Buyback Plan.	23-07-12	CI
Hisamitsu Pharmaceutical Affirms Final Dividend on Higher FY23 Profit, Revenue	23-04-14	MT

Chart Hisamitsu Pharmaceutical Co., Inc.

Duration

Period

Chart Hisamitsu Pharmaceutical Co., Inc.

More charts

Company Profile

Hisamitsu Pharmaceutical Co Inc is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the manufacture, sale and supply of pharmaceuticals and related products, and the operation of over-the-counter drug (OTC) business. It is also engaged in the manufacture and sale of drugs in the United States, Brazil, Vietnam, and Indonesia, the development work in Europe, the drug marketing and sales in China and Hong Kong. It is also engaged in the urban cable television broadcasting business, Internet connection service business, non-life insurance agency business, advertising agency business and the purchase, manufacture and sale of packing materials.

Sector

Pharmaceuticals

Calendar

2024-08-28 - Détachement de for dividende intermédiaire

More about the company

Income Statement Evolution

More financial data

Ratings for Hisamitsu Pharmaceutical Co., Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3,954 JPY

Average target price

3,950 JPY

Spread / Average Target

-0.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HISAMITSU PHARMACEUTICAL CO., INC.	-8.28%	1.84B
ELI LILLY AND COMPANY	+62.66%	854B
NOVO NORDISK A/S	+40.42%	636B
JOHNSON & JOHNSON	-4.37%	361B
MERCK & CO., INC.	+17.16%	324B
ABBVIE INC.	+9.87%	301B
ASTRAZENECA PLC	+15.66%	247B
ROCHE HOLDING AG	+4.21%	230B
NOVARTIS AG	+17.90%	228B
AMGEN INC.	+14.86%	177B

Other Pharmaceuticals